Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhi

Ketcham, John M.; Haling, Jacob; Khare, Shilpi; Bowcut, Vickie; Briere, David M.; Burns, Aaron C.; Gunn, Robin J.; Ivetac, Anthony; Kuehler, Jon; Kulyk, Svitlana; Laguer, Jade; Lawson, J. David; Moya, Krystal; Nguyen, Natalie; Rahbaek, Lisa; Saechao, Barbara; Smith, Christopher R.; Sudhakar, Niranjan; Thomas, Nicole C.; Vegar, Laura; Vanderpool, Darin; Wang, Xiaolun; Yan, Larry; Olson, Peter; Christensen, James G.; Marx, Matthew A.

doi:10.1021/acs.jmedchem.2c00741

Title: Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhi

Journal Article · 01 July 2022 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.2c00741· OSTI ID:1900762

Ketcham, John M.; Haling, Jacob; Khare, Shilpi; Bowcut, Vickie; Briere, David M.; Burns, Aaron C.; Gunn, Robin J.; Ivetac, Anthony; Kuehler, Jon; Kulyk, Svitlana; Laguer, Jade; Lawson, J. David; Moya, Krystal; Nguyen, Natalie; Rahbaek, Lisa; Saechao, Barbara; Smith, Christopher R.; Sudhakar, Niranjan; Thomas, Nicole C.; Vegar, Laura more »

Cite

Export

Save

Research Organization:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1900762

Journal Information:: J. Med. Chem., Vol. 65, Issue (14)

Country of Publication:: United States

Language:: ENGLISH

References (40)

RAS Proteins and Their Regulators in Human Disease Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank Cell, Vol. 170, Issue 1 https://doi.org/10.1016/j.cell.2017.06.009	journal	June 2017
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRAS ^G12C Inhibitor for the Treatment of Cancer Fell, Jay B.; Fischer, John P.; Baer, Brian R. Journal of Medicinal Chemistry, Vol. 63, Issue 13 https://doi.org/10.1021/acs.jmedchem.9b02052	journal	April 2020
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1) Ou, Sai-Hong Ignatius; Jänne, Pasi A.; Leal, Ticiana A. Journal of Clinical Oncology, Vol. 40, Issue 23 https://doi.org/10.1200/JCO.21.02752	journal	August 2022
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS^G12C mutation. Bekaii-Saab, Tanios S.; Spira, Alexander I.; Yaeger, Rona Journal of Clinical Oncology, Vol. 40, Issue 4_suppl https://doi.org/10.1200/JCO.2022.40.4_suppl.519	journal	February 2022
Discovery of a Covalent Inhibitor of KRAS ^G12C (AMG 510) for the Treatment of Solid Tumors Lanman, Brian A.; Allen, Jennifer R.; Allen, John G. Journal of Medicinal Chemistry, Vol. 63, Issue 1 https://doi.org/10.1021/acs.jmedchem.9b01180	journal	December 2019
Sotorasib for Lung Cancers with KRAS p.G12C Mutation Skoulidis, Ferdinandos; Li, Bob T.; Dy, Grace K. New England Journal of Medicine, Vol. 384, Issue 25 https://doi.org/10.1056/NEJMoa2103695	journal	June 2021
The structural basis of the activation of Ras by Sos Boriack-Sjodin, P. Ann; Margarit, S. Mariana; Bar-Sagi, Dafna Nature, Vol. 394, Issue 6691 https://doi.org/10.1038/28548	journal	July 1998
Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS Sheffels, Erin; Kortum, Robert L. Journal of Medicinal Chemistry, Vol. 64, Issue 10 https://doi.org/10.1021/acs.jmedchem.1c00698	journal	May 2021
Targeting Son of Sevenless 1: The pacemaker of KRAS Kessler, Dirk; Gerlach, Daniel; Kraut, Norbert Current Opinion in Chemical Biology, Vol. 62 https://doi.org/10.1016/j.cbpa.2021.02.014	journal	June 2021
Mammalian Son of Sevenless Guanine Nucleotide Exchange Factors: Old Concepts and New Perspectives Rojas, J. M.; Oliva, J. L.; Santos, E. Genes & Cancer, Vol. 2, Issue 3 https://doi.org/10.1177/1947601911408078	journal	March 2011
SOS GEFs in health and disease Baltanás, Fernando C.; Zarich, Natasha; Rojas-Cabañeros, Jose M. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Vol. 1874, Issue 2 https://doi.org/10.1016/j.bbcan.2020.188445	journal	December 2020
Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2 Corbalan-Garcia, S.; Yang, S. S.; Degenhardt, K. R. Molecular and Cellular Biology, Vol. 16, Issue 10 https://doi.org/10.1128/MCB.16.10.5674	journal	October 1996
Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis Jeng, Hao-Hsuan; Taylor, Laura J.; Bar-Sagi, Dafna Nature Communications, Vol. 3, Issue 1 https://doi.org/10.1038/ncomms2173	journal	January 2012
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants Scheffzek, K. Science, Vol. 277, Issue 5324 https://doi.org/10.1126/science.277.5324.333	journal	July 1997
Decreased GTPase activity of K- ras mutants deriving from human functional adrenocortical tumours Lin, S-R; Hsu, C-H; Tsai, J-H British Journal of Cancer, Vol. 82, Issue 5 https://doi.org/10.1054/bjoc.1999.1039	journal	March 2000
Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS Margarit, S. Mariana; Sondermann, Holger; Hall, Brian E. Cell, Vol. 112, Issue 5 https://doi.org/10.1016/S0092-8674(03)00149-1	journal	March 2003
Oncogenic Signaling Pathways in The Cancer Genome Atlas Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua Cell, Vol. 173, Issue 2 https://doi.org/10.1016/j.cell.2018.03.035	journal	April 2018
A Mutation in the SOS1 Gene Causes Hereditary Gingival Fibromatosis Type 1 Hart, Thomas C.; Zhang, Yingze; Gorry, Michael C. The American Journal of Human Genetics, Vol. 70, Issue 4 https://doi.org/10.1086/339689	journal	April 2002
Germ Line Gain of Function with SOS1 Mutation in Hereditary Gingival Fibromatosis Jang, Shyh-Ing; Lee, Eun-Jin; Hart, P. Suzanne Journal of Biological Chemistry, Vol. 282, Issue 28 https://doi.org/10.1074/jbc.M701609200	journal	May 2007
Germline gain-of-function mutations in SOS1 cause Noonan syndrome Roberts, Amy E.; Araki, Toshiyuki; Swanson, Kenneth D. Nature Genetics, Vol. 39, Issue 1 https://doi.org/10.1038/ng1926	journal	December 2006
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome Tartaglia, Marco; Pennacchio, Len A.; Zhao, Chen Nature Genetics, Vol. 39, Issue 1 https://doi.org/10.1038/ng1939	journal	December 2006
Noonan syndrome patient-specific induced cardiomyocyte model carrying SOS1 gene variant c.1654A>G Gurusamy, Narasimman; Rajasingh, Sheeja; Sigamani, Vinoth Experimental Cell Research, Vol. 400, Issue 1 https://doi.org/10.1016/j.yexcr.2021.112508	journal	March 2021
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange Burns, Michael C.; Sun, Qi; Daniels, R. Nathan Proceedings of the National Academy of Sciences, Vol. 111, Issue 9 https://doi.org/10.1073/pnas.1315798111	journal	February 2014
Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling Abbott, Jason R.; Hodges, Timothy R.; Daniels, R. Nathan Journal of Medicinal Chemistry, Vol. 61, Issue 14 https://doi.org/10.1021/acs.jmedchem.8b00360	journal	June 2018
Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS Abbott, Jason R.; Patel, Pratiq A.; Howes, Jennifer E. ACS Medicinal Chemistry Letters, Vol. 9, Issue 9 https://doi.org/10.1021/acsmedchemlett.8b00296	journal	August 2018
High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling Burns, Michael C.; Howes, Jennifer E.; Sun, Qi Analytical Biochemistry, Vol. 548 https://doi.org/10.1016/j.ab.2018.01.025	journal	May 2018
Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS Hodges, Timothy R.; Abbott, Jason R.; Little, Andrew J. Journal of Medicinal Chemistry, Vol. 61, Issue 19 https://doi.org/10.1021/acs.jmedchem.8b01108	journal	May 2018
Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1 Howes, Jennifer E.; Akan, Denis T.; Burns, Michael C. Molecular Cancer Therapeutics, Vol. 17, Issue 5 https://doi.org/10.1158/1535-7163.MCT-17-0666	journal	February 2018
Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses Akan, Denis T.; Howes, Jennifer E.; Sai, Jiqing ACS Chemical Biology, Vol. 14, Issue 3 https://doi.org/10.1021/acschembio.8b00869	journal	February 2019
Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods Sarkar, Dhruba; Olejniczak, Edward T.; Phan, Jason Journal of Medicinal Chemistry, Vol. 63, Issue 15 https://doi.org/10.1021/acs.jmedchem.0c00511	journal	July 2020
Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation Winter, Jon J. G.; Anderson, Malcolm; Blades, Kevin Journal of Medicinal Chemistry, Vol. 58, Issue 5 https://doi.org/10.1021/jm501660t	journal	February 2015
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction Hillig, Roman C.; Sautier, Brice; Schroeder, Jens Proceedings of the National Academy of Sciences, Vol. 116, Issue 7 https://doi.org/10.1073/pnas.1812963116	journal	January 2019
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition Hofmann, Marco H.; Gmachl, Michael; Ramharter, Juergen Cancer Discovery, Vol. 11, Issue 1 https://doi.org/10.1158/2159-8290.CD-20-0142	journal	January 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS Ramharter, Juergen; Kessler, Dirk; Ettmayer, Peter Journal of Medicinal Chemistry, Vol. 64, Issue 10 https://doi.org/10.1021/acs.jmedchem.0c01949	journal	March 2021
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations Zhou, Chuan; Fan, Zisheng; Zhou, Zehui Journal of Medicinal Chemistry, Vol. 65, Issue 5 https://doi.org/10.1021/acs.jmedchem.1c01774	journal	March 2022
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy Ayati, Adileh; Moghimi, Setareh; Salarinejad, Somayeh Bioorganic Chemistry, Vol. 99 https://doi.org/10.1016/j.bioorg.2020.103811	journal	June 2020
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery Manevski, Nenad; King, Lloyd; Pitt, William R. Journal of Medicinal Chemistry, Vol. 62, Issue 24 https://doi.org/10.1021/acs.jmedchem.9b00875	journal	August 2019
Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers. Kris, Mark G.; Offin, Michael David; Feldman, Daniel L. Journal of Clinical Oncology, Vol. 36, Issue 15_suppl https://doi.org/10.1200/JCO.2018.36.15_suppl.9081	journal	May 2018
Frequency and outcomes of brain metastases in patients withHER2‐mutant lung cancers Offin, Michael; Feldman, Daniel; Ni, Ai Cancer, Vol. 125, Issue 24 https://doi.org/10.1002/cncr.32461	journal	August 2019
CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective Lin, Jiunn Current Drug Metabolism, Vol. 9, Issue 1 https://doi.org/10.2174/138920008783331077	journal	January 2008

Similar Records

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway

Journal Article · 2023 · Journal of Medicinal Chemistry · OSTI ID:1900762

Ikeda, Zenichi; Kamei, Taku; Sasaki, Yusuke; +15 more

The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer

Journal Article · 2013 · J. Med. Chem. · OSTI ID:1900762

Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; +17 more

Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Journal Article · 2013 · J. Med. Chem. · OSTI ID:1900762

Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; +49 more

Title: Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhi

Citation Formats

References (40)

Similar Records

Related Subjects